Literature DB >> 30431333

A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction.

Anne-Lise Rossi1, Marilyn Le1, Chun-Shiang Chung1, Yaping Chen1, Eleanor A Fallon1, Andres Matoso2,3, Shumin Xu1,4, Tristen T Chun1, Craig P Erickson1, Alfred Ayala1.   

Abstract

The liver is an organ that, when dysfunctional in a septic patient, is strongly associated with morbidity and mortality. Understanding the pathophysiology of liver failure during sepsis may lead to improved diagnostics and potential therapeutic targets. Historically, programmed cell death receptor (PD) ligand 1 (PD-L1) has been considered the primary ligand for its checkpoint molecule counterpart, PD-1, with PD-L2 rarely in the immunopathological spotlight. PD-1 and PD-L1 contribute to liver dysfunction in a murine cecal ligation and puncture (CLP) model of sepsis, but virtually nothing is known about PD-L2's role in sepsis. Therefore, our central hypothesis was that sepsis-induced changes in hepatic PD-L2 expression contributed to worsened liver function and, subsequently, more pronounced morbidity and mortality. We found that although PD-L1 gene deficiency attenuated the hepatic dysfunction seen in wild-type mice after CLP, the loss of PD-L2 appeared to actually worsen indices of liver function along with a trend toward higher liver tissue vascular permeability. Conversely, some protective effects of PD-L2 gene deletion were noted, such as reduced liver/peritoneal bacterial load and reduced IL-6, IL-10, and macrophage inflammatory protein 2 levels following CLP. These diverse actions, as well as the unique expression pattern of PD-L2, may explain why no overt survival advantage could be witnessed in the septic PD-L2-/- mice. Taken together, these data suggest that although PD-L2 has some selective effects on the hepatic response seen in the septic mouse, these factors are not sufficient to alter septic mortality in this adult murine model. NEW & NOTEWORTHY Our study shows not only that ligands of the checkpoint protein PD-1 respond inversely to a stressor such as septic challenge (PD-L2 declines, whereas PD-L1 rises) but also that aspects of liver dysfunction increase in septic mice lacking the PD-L2 gene. Furthermore, these differences in PD-L2 gene-deficient animals culminated in the abrogation of the survival advantage seen in the septic PD-L1-knockout mice, suggesting that PD-L2 may have roles beyond a simple immune tolerogen.

Entities:  

Keywords:  inflammation; posttranslational modification; programmed cell death receptor ligand 1; programmed cell death receptor-1; sepsis

Mesh:

Substances:

Year:  2018        PMID: 30431333      PMCID: PMC6383374          DOI: 10.1152/ajpgi.00204.2018

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  29 in total

Review 1.  Genotype to phenotype: challenges and opportunities.

Authors:  D P Holschneider; J C Shih
Journal:  Int J Dev Neurosci       Date:  2000-10       Impact factor: 2.457

2.  Benchmarking the incidence and mortality of severe sepsis in the United States.

Authors:  David F Gaieski; J Matthew Edwards; Michael J Kallan; Brendan G Carr
Journal:  Crit Care Med       Date:  2013-05       Impact factor: 7.598

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Effect of PD-1: PD-L1 in Invariant Natural Killer T-Cell Emigration and Chemotaxis Following Sepsis.

Authors:  John S Young; Daithi S Heffernan; Chun-Shiang Chung; Maude L Kettenmann; Whitney A Young; Valeria Sanabria Guillen; William G Cioffi; Alfred Ayala
Journal:  Shock       Date:  2016-05       Impact factor: 3.454

5.  Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease.

Authors:  Raphaël M Zellweger; Tyler R Prestwood; Sujan Shresta
Journal:  Cell Host Microbe       Date:  2010-02-18       Impact factor: 21.023

Review 6.  Management of sepsis in patients with liver failure.

Authors:  Juan M Canabal; David J Kramer
Journal:  Curr Opin Crit Care       Date:  2008-04       Impact factor: 3.687

7.  A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome.

Authors:  P C Hebert; A J Drummond; J Singer; G R Bernard; J A Russell
Journal:  Chest       Date:  1993-07       Impact factor: 9.410

8.  IL-33 promotes DC development in BM culture by triggering GM-CSF production.

Authors:  Nobuyasu Mayuzumi; Hironori Matsushima; Akira Takashima
Journal:  Eur J Immunol       Date:  2009-12       Impact factor: 5.532

9.  Kupffer cells protect liver sinusoidal endothelial cells from Fas-dependent apoptosis in sepsis by down-regulating gp130.

Authors:  Noelle A Hutchins; Chun-Shiang Chung; Joshua N Borgerding; Carol A Ayala; Alfred Ayala
Journal:  Am J Pathol       Date:  2013-01-07       Impact factor: 4.307

10.  Splenic CD4+ T Cells in Progressive Visceral Leishmaniasis Show a Mixed Effector-Regulatory Phenotype and Impair Macrophage Effector Function through Inhibitory Receptor Expression.

Authors:  Audrie A Medina-Colorado; Elvia Y Osorio; Omar A Saldarriaga; Bruno L Travi; Fanping Kong; Heidi Spratt; Lynn Soong; Peter C Melby
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

View more
  3 in total

1.  Publication trends of research on sepsis and programmed cell death during 2002-2022: A 20-year bibliometric analysis.

Authors:  Jing-Yan Li; Ren-Qi Yao; Min-Yue Xie; Qi-Yuan Zhou; Peng-Yue Zhao; Ying-Ping Tian; Yong-Ming Yao
Journal:  Front Cell Infect Microbiol       Date:  2022-09-23       Impact factor: 6.073

Review 2.  The Pathogenesis of Sepsis and Potential Therapeutic Targets.

Authors:  Min Huang; Shaoli Cai; Jingqian Su
Journal:  Int J Mol Sci       Date:  2019-10-29       Impact factor: 5.923

Review 3.  Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression.

Authors:  Margaret A McBride; Tazeen K Patil; Julia K Bohannon; Antonio Hernandez; Edward R Sherwood; Naeem K Patil
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.